Genaera — Corporate Update (April 2004)
14 slides from Genaera's corporate update, Apr 23, 2004
Slide 1: Genaera is a biopharmaceutical company
Genaera is a biopharmaceutical company committed to developing medicines derived from genomics and natural products for serious diseases. Research and development efforts are focused on anti-angiogenesis and respiratory diseases. © 2004 Genaera Corporation or its affiliates. All rights reserved. 1
Slide 2: Forward-Looking Statements
Forward-Looking Statements This announcement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties, known and unknown. Forward-looking statements reflect management’s current views and are based on c
Slide 3: Conference Call Agenda
Conference Call Agenda Introduction Roy Levitt, MD President and Chief Executive Officer AMD Program Update Roger Vogel, MD Acting Chief Medical Officer Q&A Session John Skolas, JD, MBA Senior Vice President, CFO & General Counsel Participation: All
Slide 4: Program Highlights
Program Highlights Three Products in Development Squalamine AMD Phase 1-2 data Ophthalmic IND “active” April 2004 NSCLC Phase 2B Prostate cancer $1.1M grant—controlled Phase 2 IL9 Antibody MEDI filed IND Phase 1 clinical start and cash milestone anticipated LOMUCINTM CFFT development alliance & $1.7
Slide 5: Anti-Angiogenic Product Squalamine Overview
Anti-Angiogenic Product Squalamine Overview . Potent direct acting anti-angiogenic small molecule ??Long intracellular half-life – dosing weekly to monthly ??Excellent safety profile as single agent ??Potential for broad use in eye diseases and cancers ??Strong patent position MSI-1256F
Slide 6: Anti-Angiogenic Product Squalamine
Anti-Angiogenic Product Squalamine . Selective membrane uptake into endothelial cells . Calmodulin-squalamine binding redistributes . Inhibits cytoskeleton . Inhibits VEGF and other growth factors . Apoptosis and vessel regression F-actin Filaments Control Squalamine
Slide 7: Regulatory Update
Regulatory Update Ophthalmic IND Activities and Timelines . Pre-IND submission to ODE V—January 30, 2004 . Pre-IND meeting ODE V—March 1, 2004 . IND submitted ODE V—March 24, 2004 . Action Letter—April 20,
Slide 8: I/II Trial Design (40 Patients)
Squalamine AMD Phase I/II Trial Design (40 Patients) VA VA VA VA Baseline 1st Week 2nd Week 3rd Week 4th Week 2 Months 4 Months Squalamine Dose, Intravenous (25 or 50 mg/m2) Abbreviation: VA = Visual Acuity Examination Note: Trial Design Diagram is Simplified
Slide 9: I/II Results Summary at Months
Squalamine AMD Phase I/II Results Summary at 4 Months . 100% of patients had preserved or improved vision . 26% of patients had significantly improved vision . Up to 8 lines of visual acuity improvement . Excellent safety profile to date . Classic and occult subtypes responding . Lesions smaller in
Slide 10: II Plans Trial (100 Patients, Randomized, Controlled, Masked)
Squalamine AMD Phase II Plans Trial 209 (100 Patients, Randomized, Controlled, Masked) Baseline Weekly X 4 Monthly X 11 12 Months 24 Months Squalamine Dose, Intravenous (20mg, 40 mg, vehicle control) Follow Up 1º endpoints: safety and visual acuity (ETDRS) 2 º endpoints, OCT, Angiograms, Fundus Phot
Slide 11: II Plans Trial (30 Patients, Randomized, Masked, Controlled, Concomitant Visudyne)
Squalamine AMD Phase II Plans Trial 208 (30 Patients, Randomized, Masked, Controlled, Concomitant Visudyne®) Verteporfin Dose, Intravenous Baseline 1st Week 2nd Week 3rd Week 4th Week 5th Week Monthly X 5 Squalamine Dose, Intravenous (20 mg, 40 mg, vehicle control) Group A: 10 patients—verteporfin p
Slide 12: II PK Study Trial (18 Patients, Open Label)
Squalamine AMD Phase II PK Study Trial 207 (18 Patients, Open Label ) PK PK F/U PK PK PK F/U PK F/U F/U Baseline 1st Week 2nd Week 3rd Week 4th Week 2 Months 4 Months Squalamine Dose, Intravenous (10, 20, 40 mg) Endpoints: Primary: safety and visual acuity (ETDRS), secondary: OCT, angiography, fundu
Slide 13: Summary of AMD Timelines Squalamine Clinical Plans
Summary of AMD Timelines Squalamine Clinical Plans Phase II . Initiate Phase II placebo controlled study (209) (Q2 ‘04) . Initiate pilot concomitant use study (208) (Q2 ‘04) . Initiate Phase II PK study (207) in AMD patients (Q2 ‘04) Phase III . Initiate Phase III studies (301 & 302) (early ‘05)
Slide 14: AMD Competitive Assessments Summary
AMD Competitive Assessments Summary . Intravenous squalamine delivery is less invasive, and avoids complications with intravitreal injections . No acute visual loss as with PDT . Potential for safer long-term maintenance therapy . Treat second eye with no additional risk or cost . Improvement or pre